We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Glenmark, InvaGen Enter Joint Generics Venture
Glenmark, InvaGen Enter Joint Generics Venture
December 16, 2005
Indian drug firm Glenmark Pharmaceuticals has signed a deal with U.S.-based InvaGen to market generic versions of seven brand drugs with a current annual U.S. market of $4.1 billion, in Glenmark’s latest move to bolster its position in the U.S. market.